| Uses of masp-2 inhibitors to treat sickle cell disease |
2023-3-13 |
2023-8-04 |
|
| Masp-2 and masp-3 inhibitors, and related compositions and methods, for … |
2023-3-09 |
2023-9-14 |
|
| Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits … |
2023-2-28 |
2023-7-20 |
|
| Therapeutic antibodies that bind to the serine protease domain of masp-2 and … |
2022-12-07 |
2023-8-24 |
|
| Masp-2 inhibitors and methods of use |
2022-11-30 |
2023-5-11 |
|
| Compositions and methods of inhibiting masp-3 for the treatment of various … |
2022-11-29 |
2023-6-01 |
|
| Compositions and Methods of Inhibiting MASP-2 for the Treatment of Various … |
2022-11-03 |
2023-7-06 |
|
| Targeted catalytic complement-activating molecules and methods of use thereof |
2022-10-06 |
2023-6-16 |
|
| Methods and compositions for treating cancer |
2022-9-13 |
2023-6-01 |
|
| Methods of inhibiting masp-2 for the treatment and/or prevention of coronavirus … |
2022-9-05 |
2022-11-01 |
|
| Treatment of addiction and impulse-control disorders using pde7 inhibitors |
2022-8-31 |
2023-4-13 |
|
| Methods for inhibiting fibrosis in a subject in need thereof |
2022-8-23 |
2022-11-10 |
|
| Chimeric inhibitor molecules of complement activation |
2022-8-09 |
2023-9-21 |
|
| Masp-2 inhibitor compounds, compositions comprising same and uses thereof |
2022-6-02 |
2022-8-01 |
|
| Masp-2 inhibitor compounds, compositions comprising same and uses thereof |
2022-6-02 |
2022-8-01 |
|
| Masp-2 inhibitors and methods of use. |
2022-6-02 |
2023-6-02 |
|
| Masp-2 inhibitors for use in treating and/or preventing idiopathic pneumonia … |
2022-5-25 |
2022-7-01 |
|
| Biomarker for assessing the risk of developing acute covid-19 and post-acute … |
2022-2-04 |
2022-8-11 |
|
| Uses for treating veno-occlusive disease associated with hematopoietic stem … |
2022-1-25 |
2023-1-27 |
|
| Anti-Inflammatory and Mydriatic Intracameral Solutions for Inhibition of … |
2021-12-17 |
2022-6-09 |
|
| Stable preservative-free mydriatic and anti-inflammatory solutions for … |
2021-12-16 |
2022-6-09 |
|
| Ophthalmologic irrigation solutions and method |
2021-12-15 |
2022-6-09 |
|
| Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors |
2021-11-18 |
2022-3-03 |
|
| Cyclooxygenase inhibitor and calcium channel antagonist compositions and … |
2021-11-11 |
2022-3-03 |
|
| Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for … |
2021-10-11 |
2022-8-04 |
|
| Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for … |
2021-10-11 |
2022-8-18 |
|
| Methods for Treating Conditions Associated with MASP-2 Dependent Complement … |
2021-9-09 |
2022-3-24 |
|
| Monoclonal antibodies, compositions and methods for detecting complement factor … |
2021-8-17 |
2022-2-24 |
|
| Human monoclonal antibodies binding to masp-2 and inhibiting masp-2 dependent … |
2021-8-10 |
2021-9-30 |
|
| Methods and compositions for treating cancer |
2021-7-12 |
2023-1-25 |
|
| Methods for Treating Conditions Associated with MASP-2 Dependent Complement … |
2021-7-09 |
2022-1-06 |
|
| Masp-2 inhibitory agents containing medicaments for inhibiting masp-2-dependent … |
2021-5-23 |
2021-7-29 |
|
| Methods for inhibiting fibrosis in a subject in need thereof |
2021-3-30 |
2021-11-18 |
|
| Masp-2 inhibitors and methods of use |
2020-12-04 |
2021-6-10 |
|
| Methods for inhibiting angiogenesis in a subject in need thereof |
2020-11-17 |
2021-6-24 |
|
| Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions … |
2020-8-04 |
2021-3-18 |
|
| Methods for Treating Conditions Associated with MASP-2 Dependent Complement … |
2020-8-04 |
2021-2-18 |
|
| Chimeric inhibitor molecules of complement activation |
2020-7-16 |
2022-9-27 |
2022-9-27 |
| Methods for reducing proteinuria in a human subject suffering from … |
2020-6-25 |
2021-3-18 |
|
| Methods for treating conditions associated with MASP-2-dependent complement … |
2020-6-05 |
2020-6-25 |
|
| Methods for Treating Conditions Associated with MASP-2 Dependent Complement … |
2020-5-12 |
2021-2-25 |
|
| Methods for treating conditions associated with masp-2 dependent complement … |
2020-4-02 |
2021-2-11 |
|
| Monoclonal Antibodies, Compositions and Methods for Detecting Mucin-like … |
2020-3-12 |
2020-11-26 |
|
| METHODS TO TREAT AND / OR PREVENT GRAFT DISEASE IN FRONT OF THE HOST AND / OR … |
2020-3-05 |
2020-4-22 |
|
| Methods for treating conditions associated with MASP-2 dependent complement … |
2020-2-21 |
2020-3-12 |
|
| Highly concentrated low-viscosity masp-2 inhibitory antibody formulations, kits … |
2020-2-18 |
2020-7-10 |
|
| Methods for reducing proteinuria in a human subject suffering from … |
2019-11-28 |
2020-4-13 |
|
| Inhibitors of GPR174 and Uses Thereof |
2019-11-13 |
2020-9-03 |
|
| Methods for treating conditions associated with masp-2 dependent complement … |
2019-10-02 |
2020-5-21 |
|
| Methods for Treating Conditions Associated with MASP-2 Dependent Complement … |
2019-9-13 |
2020-6-18 |
|
| Compositions and methods of inhibiting MASP-2 for the treatment of various … |
2019-6-20 |
2021-8-31 |
|
| Masp-2 inhibitors and methods of use |
2019-5-29 |
2019-12-05 |
|
| Methods for Treating Conditions Associated with MASP-2 Dependent Complement … |
2019-4-08 |
2020-2-06 |
|
| TREATMENT OF ADDICTION DISORDERS AND IMPACT CONTROL USING PDE7 SUSPENSES |
2019-2-20 |
2020-5-29 |
|
| Method of Identifying Transmembrane Protein-interacting Compounds |
2018-12-18 |
2019-10-17 |
|
| Use of pde7 inhibitors for the treatment of movement disorders |
2018-12-06 |
2019-6-20 |
|
| Treatment of Addiction and Impulse-control Disorders Using PDE7 Inhibitors |
2018-11-14 |
2019-5-09 |
|
| USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOTIVATION DISORDERS |
2018-10-11 |
2020-5-29 |
|
| Methods for treating and/or preventing graft-versus-host disease and/or diffuse … |
2018-8-14 |
2020-10-23 |
|
| Compositions and methods for prophylaxis and treatment of addictions |
2018-7-26 |
2019-1-24 |
|
| Compositions and methods of inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for … |
2018-6-15 |
2018-7-05 |
|
| Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP- … |
2018-4-11 |
2018-10-11 |
|
| Compositions and methods for prophylaxis and treatment of addictions |
2018-3-27 |
2018-4-19 |
|
| Ophthalmologic irrigation solutions and method |
2018-2-07 |
2018-2-22 |
|
| Stable Anti-inflammatory Solutions for Injection |
2018-1-31 |
2018-12-06 |
|
| Methods for treating conditions associated with MASP-2 dependent complement … |
2018-1-19 |
2018-2-08 |
|
| Pde10 inhibitor compounds, compositions comprising same and uses thereof |
2017-10-24 |
2017-12-31 |
|
| Methods for reducing proteinuria in a human subject suffering from … |
2017-10-12 |
2022-3-01 |
|
| Pde10 inhibitors and related compositions and methods |
2017-9-01 |
2018-5-03 |
|
| Highly concentrated low viscosity masp-2 inhibitory antibody formulations, kits … |
2017-8-30 |
2022-1-06 |
|
| Highly concentrated low viscosity MASP-2 inhibitory antibody formulations, kits … |
2017-8-30 |
2020-4-24 |
|
| ANTIBODIES THAT JOIN MASP-3 (SERINA PROTEASA 3 ASSOCIATED BY MORNING) |
2017-8-01 |
2019-4-17 |
|
| Compositions and methods of inhibiting masp-3 for the treatment of various … |
2017-7-31 |
2022-2-01 |
|
| Compositions and methods of inhibiting MASP-3 for the treatment of various … |
2017-7-31 |
2020-10-23 |
|
| Compositions and methods of inhibiting MASP-3 for the treatment of various … |
2017-7-31 |
2022-3-25 |
|
| METHODS FOR TREATMENT OF CONDITIONS RELATED TO MASP-2 ADDITIONAL ACTIVATION … |
2017-6-13 |
2018-2-14 |
|
| Masp isoforms as inhibitors of complement activation |
2017-5-31 |
2017-11-23 |
|
| Processes and intermediates for the preparation of a pde10 inhibitor |
2017-4-07 |
2018-3-01 |
|
| Methods for inhibiting angiogenesis in a subject in need thereof. |
2017-3-31 |
2019-11-22 |
|
| Methods of generating bioactive peptide-bearing antibodies and compositions … |
2017-3-15 |
2021-6-29 |
2021-6-29 |
| Methods for inhibiting fibrosis in a subject in need thereof. |
2017-1-05 |
2019-7-19 |
|
| Methods for Treating Conditions Associated with MASP-2 Dependent Complement … |
2016-12-27 |
2017-6-15 |
|
| G Protein Coupled Receptors and Uses Thereof |
2016-11-10 |
2017-7-06 |
|
| Genetically modified non-human mammals and cells |
2016-11-10 |
2017-5-11 |
|
| Methods of treating disease states associated with masp-2-dependent complement … |
2016-11-09 |
2019-8-30 |
|
| Methods for treating conditions associated with masp-2 dependent complement … |
2016-11-09 |
2019-4-08 |
|
| Solid state forms of a PDE10 inhibitor |
2016-11-04 |
2018-3-20 |
2018-3-20 |
| Optically active pde10 inhibitor, compositions comprising same, proceses for … |
2016-10-27 |
2019-9-26 |
|
| Compositions and methods for prophylaxis and treatment of addictions |
2016-8-08 |
2018-9-04 |
2018-9-04 |
| PDE10 inhibitors and related compositions and methods |
2016-8-04 |
2018-10-23 |
2018-10-23 |
| Mixed micelles |
2016-2-19 |
2017-5-23 |
2017-5-23 |
| G protein coupled receptors and uses thereof |
2016-1-27 |
2016-9-29 |
|
| Inducible mutagenesis of target genes |
2015-12-23 |
2016-7-14 |
|
| Compositions for inhibiting MASP-2 dependent complement activation |
2015-12-16 |
2017-9-28 |
2017-9-28 |